Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

about

Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.

P2860

Q50110556-4BED944A-8F89-46D4-A0F9-99B3978488FB

P2860

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Item

http://www.wikidata.org/entity/Q39227773

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

@en

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.

@nl

type

Item

label

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

@en

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.

@nl

prefLabel

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

@en

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.

@nl

P1476

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

@en

P2093

C J Owen

http://www.w3.org/2001/XMLSchema#string

C L Toze

http://www.w3.org/2001/XMLSchema#string

C Shustik

http://www.w3.org/2001/XMLSchema#string

I Bence-Bruckler

http://www.w3.org/2001/XMLSchema#string

R Delage

http://www.w3.org/2001/XMLSchema#string

S Coutre

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Genomic aberrations and survival in chronic lymphocytic leukemia

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

P304

1185-1196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S00277-017-2982-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28389687

http://www.w3.org/2001/XMLSchema#string

P921

chronic lymphocytic leukemia

leukemia

lymphocyte

P932

5486803

http://www.w3.org/2001/XMLSchema#string

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

about

P2860

P2860

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932